TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In: 25 Mar, 2025
Code: CMI4321
Pages: 160
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.

Market Dynamics

Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).

However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.

Key features of the study:

This report provides in-depth analysis of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Detailed Segmentation:

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type:
- Hereditary Transthyretin Amyloidosis (hATTR)
- Wild Type Transthyretin Amyloidosis (wtATTR)
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type:
- Transthyretin Stabilizers
- Nonsteroidal anti-inflammatory drugs (NSAID)
- RNAi therapy
- Others
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region:
- North America
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal anti-inflammatory drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - U.S.
    - Canada
- Latin America
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal anti-inflammatory drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country:
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
    - Others
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Type:
    - Hereditary Transthyretin Amyloidosis (hATTR)
    - Wild Type Transthyretin Amyloidosis (wtATTR)
  - By Drug Type:
    - Transthyretin Stabilizers
    - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
    - RNAi therapy
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Pfizer Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- GlaxoSmithKline Plc.
- Eidos Therapeutics
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals
- Prothena Corporation plc
- Intellia Therapeutics, Inc.
- Corino Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

By Type:

Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)

By Drug Type:

Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
Rnai Therapy
Others

By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

By Type:

By Drug Type:

By Distribution Channel:

By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :